On October 14, 2024 MEDiC Life Sciences ("MEDiC"), a Silicon Valley biotech startup, reported that it has entered a research collaboration with Hanmi Pharmaceutical ("Hanmi"), a leading biopharma company in Korea (Press release, MEDIC Life Sciences, OCT 14, 2024, View Source [SID1234647188]). In this collaboration, MEDiC will use its MCAT platform to identify cancer biomarkers for one of Hanmi’s clinical assets.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
MCAT is MEDiC’s next-generation functional genomics platform that can simultaneously measure millions of gene-to-drug interactions between a cancer drug and all possible genetic mutations. Using this platform, MEDiC identifies SLS biomarkers—a set of multiple genetic mutations that exhibit synthetic lethality with a given cancer drug—maximizing response rates in patients whose cancer harbors any of these mutations. This platform can also expand the market potential of cancer drugs by providing multiple biomarkers, whose combined prevalence in patients can be significant.
"We are very excited that Hanmi Pharmaceutical, a leading biopharma company, has selected MEDiC as a collaborator to advance its oncology programs," said Kyuho Han, Ph.D., co-founder and chief executive officer of MEDiC. "We look forward to working with Hanmi to identify synthetic lethal biomarkers for their clinical assets, advancing effective new treatments for cancer patients."
Under the terms of the agreement, MEDiC has received upfront payments for the research collaboration and a strategic investment from Hanmi.
In Young Choi, Head of Hanmi’s R&D Center, stated, "Hanmi is conducting research on various cancer therapeutics, including immuno-oncology, and targeted therapies, achieving meaningful results in the clinical development of innovative cancer drugs." He added, "Through this collaboration with MEDiC, which possesses outstanding biomarker technology, we expect to strengthen the value of Hanmi’s new cancer drugs by improving the possibility of success in clinical trials." He also stated, "Along with research collaboration, strategic investment will empower the relationship between Hanmi and MEDiC, allowing the synergy by ascending the value of assets for each company."
MEDiC has developed a proprietary functional genomics platform that uses patient tumor-like cancer models to identify optimal gene targets and biomarkers for cancer treatment. While functional genomics approaches have been widely used to screen whole genomes for gene functions in cancer, MEDiC is the first to demonstrate that using 3D tumor models, rather than traditional 2D cultures, can significantly improve the accuracy and translatability of functional genomics. With this technology, MEDiC can identify novel cancer targets and biomarkers for developing drugs for solid tumor indications. MEDiC’s unique approach has already attracted partners, including Bristol Myers Squibb, Hanmi Pharmaceutical, and other undisclosed companies, who are seeking novel targets and biomarkers for drug development.